Avidity Biosciences' Muscle Disease Candidate Shows Improvement in Multiple Additional Functional Endpoints, Safety
Portfolio Pulse from Vandana Singh
Avidity Biosciences Inc announced new data for its lead clinical program, AOC 1001, showing improvement in multiple functional endpoints and favorable long-term safety for myotonic dystrophy type 1 (DM1). The data from the Phase 1/2 MARINA trial and MARINA open-label extension study will be highlighted at the 28th Annual Congress of the World Muscle Society. The company plans to share AOC 1001 data from the MARINA-OLE study in the first half of 2024 and is finalizing the Phase 3 study design and global regulatory path for AOC 1001. RNA shares are down 1.13% at $6.12 on the last check Monday.
October 09, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avidity Biosciences' AOC 1001 shows promising results in treating DM1, with plans to share more data in 2024. Despite the positive news, RNA shares are down 1.13%.
The announcement of positive results from Avidity Biosciences' AOC 1001 clinical program is a significant development for the company. However, despite the positive news, the company's stock price has fallen, indicating that the market may have already priced in this information or there are other factors at play affecting the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100